Bioventus Inc.: Form 10-Q for the period ended Apr 3, 2021
Filed with the SEC on May 13, 2021 and accepted by EDGAR at May 13, 2021, 08:59 ET.
Management's discussion and analysis
As filed, 31,102 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of Bioventus Inc.’s (sometimes referred to as “we,” “us,” “our” or “Bioventus”) financial condition and results of operations should be read in conjunction with the “Special Note Regarding Forward-Looking Statements” and our unaudited consolidated condensed financial statements and related notes thereto appearing elsewhere in this Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 26, 2021 (2020 10-K).
Executive Summary
We are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. We operate our business through two reportable segments, U.S. and International, and our portfolio of products is grouped into three verticals, which we updated during the three months ended April 3, 2021 as a result of our acquisition of Bioness Inc. (Bioness).
- Pain Treatments and Joint Preservation includes the legacy osteoarthritis (OA) joint pain treatment and joint preservation products, plus the Peripheral Nerve Stimulation products sold previously by Bioness.
- Bone Graft Substitutes (BGS) remains unchanged. This vertical is comprised of human tissue allograft and synthetic products used primarily in spine surgery which have either (i) received 510(k) clearance, which is a premarket submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device, or (ii) are regulated solely as Section 361 HCT/Ps, which means they are human cells, tissues and cellular and tissue-based products that do not require a PMA in the United States; and
- Restorative Therapies includes the legacy Minimally invasive fracture treatments, plus the rehabilitation products sold previously by Bioness. Restorative Therapies encompass our FDA-approved Exogen system prescribed for long bone stimulation for fracture healing.
The following table sets forth total net sales, net income and Adjusted EBITDA:
| Three Months Ended April 3, 2021 | March 28, 2020 | |
|---|---|---|
| Net sales | $81,778 | $78,645 |
| Net income | $24,528 | $10,486 |
| Adjusted EBITDA(1) | $11,070 | $14,246 |
(1) See below under results of operations-Adjusted EBITDA for a reconciliation of net income to Adjusted EBITDA.
Recent Developments
Bioness Acquisition
On March 30, 2021, we completed the acquisition of Bioness, a global leader in neuromodulation and advanced rehabilitation medical devices through its innovative peripheral nerve stimulation (PNS) therapy and premium advanced rehabilitation solutions.
The Bioness acquisition gives Bioventus access into two large and growing markets: PNS and the advanced rehabilitation market, and we estimate their medical devices address total global market opportunities approaching $8 billion per year.
We believe both of these markets offer attractive growth opportunities driven by demographic trends and the need for safe, effective, treatment options for the many patients suffering from post-surgical pain, stroke, multiple sclerosis, traumatic brain injury, spinal cord injury and cerebral palsy.
Bioness advanced rehabilitation solutions have a broad portfolio of offerings, including proprietary electrical stimulation exoskeletal devices for both the upper and lower extremities, robotic gait and fall safety systems, and high-tech, interactive software learning and recovery assessment platforms.
Bioness PNS Systems help patients suffering from pain after surgery on an extremity, which affects over 16 million patients each year globally, and addresses the growing need to reduce opioid usage.
Under the merger agreement, we paid $48.9 million at the closing of the transaction and agreed to pay up to an additional $43.0 million of discounted contingent consideration related to the achievement of certain key milestones (the Bioness Merger Agreement). The acquisition includes the entire portfolio of Bioness products as well as its research and development pipeline. The up-front consideration was funded exclusively through the use of cash on hand.
BONES Trial
We submitted a supplemental PMA to the FDA in December 2020 seeking approval of an expanded indication for EXOGEN, specifically, for the adjunctive treatment of acute and delayed metatarsal fractures to reduce the risk of non-union. This PMA supplement was based on and supported by clinical data in metatarsal fractures from the ongoing B.O.N.E.S. study. In April 2021, we received a letter from the FDA identifying certain deficiencies in the PMA supplement that must be addressed before the FDA can complete its review of the PMA supplement. The deficiencies include concerns about the data and endpoints from the B.O.N.E.S. study, and requests for re-analyses of certain data and provision of other information to support the findings. We are currently evaluating the FDA’s comments and preparing our response to the FDA letter. We can give no assurance that we will be able to resolve the deficiencies identified by the FDA in a timely manner, or at all. Consequently, the FDA’s decision on the PMA supplement may be delayed beyond the time originally anticipated. Moreover, if our responses do not satisfy the FDA’s concerns, the FDA may not approve our PMA supplement seeking to expand the indications for use of EXOGEN as proposed.
COVID-19 pandemic impact
In 2020, the COVID-19 pandemic spread around the world and in the United States. New variants of the virus have emerged, some of which have shown to be more contagious. The COVID-19 pandemic has had widespread, rapidly evolving and unpredictable impacts on global society, economies, financial markets and business practices. Federal and state governments have implemented measures in an effort to prevent or minimize the spread of the virus, and ongoing effects of the pandemic, including social distancing, travel restrictions, border closures, limitations on public gatherings, mandatory closure or reduced capacity of business, work from home, supply chain logistical changes and other measures, which have caused global business disruptions and significant volatility in U.S. and international debt and equity markets. Our business, results of operations and financial condition have been and may continue to be, materially impacted by fluctuations in patient visits and elective procedures and could be further impacted by any future temporary cessations of elective procedures, delays in payments from customers, supply chain interruptions, extended “shelter-in-place” orders or advisories, facility closures or other reasons related to the pandemic. Furthermore, the long-term impact of COVID-19 on our business will depend on many factors, including, but not limited to, the duration and severity of the pandemic, new and ongoing measures taken in response to the pandemic, the availability and effectiveness of vaccines, the impact on economic activity from the pandemic and actions taken in response and the resulting impact it has on our partners, patients and communities in which we operate, all of which continue to be uncertain. As of the date of this Quarterly Report on Form 10-Q, the extent to which COVID-19 could materially impact the Company’s financial conditions, liquidity or results of operations is uncertain.
To the extent COVID-19 disruptions continue to adversely impact our business, results of operations and financial condition, it may also have the effect of heightening risks relating to our ability to successfully commercialize new developed or acquired products or therapies, consolidation in the healthcare industry, intensified pricing pressure as a result of changes in the purchasing behavior of hospitals and maintenance of our numerous contractual relationships. For additional information on the risks we may face as a result of COVID-19, refer to Part I, Item 1A. Risk Factors – Our business may continue to experience adverse impacts as a result of the COVID-19 pandemic in our 2020 10-K.
Results of Operations
For a description of the components of our results of operations, refer to Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2020 10-K.
The following table sets forth components of our condensed consolidated statements of operations as a percentage of net sales for the periods presented:
| Three Months Ended April 3, 2021 | March 28, 2020 | |
|---|---|---|
| Net sales | 100.0% | 100.0% |
| Cost of sales (including depreciation and amortization) | 27.2% | 27.2% |
| Gross profit | 72.8% | 72.8% |
| Selling, general and administrative expense | 42.3% | 51.3% |
| Research and development expense | 1.2% | 2.7% |
| Depreciation and amortization | 2.4% | 2.3% |
| Operating income | 26.9% | 16.5% |
20
The following table presents a reconciliation of net income to Adjusted EBITDA for the periods presented:
(in thousands)
| Three Months Ended April 3, 2021 | March 28, 2020 | |
|---|---|---|
| Net income | $24,528 | $10,486 |
| Depreciation and amortization (a) | 7,184 | 7,265 |
| Income tax (benefit) expense | (73) | 39 |
| Interest (income) expense | (2,876) | 2,381 |
| Equity compensation (b) | (22,412) | (7,026) |
| Succession and transition charges (c) | 157 | 773 |
| Foreign currency impact (d) | (52) | 86 |
| Acquisition costs(e) | 3,196 | — |
| Equity loss in unconsolidated investments(f) | 469 | — |
| Other non-recurring costs (g) | 949 | 242 |
| Adjusted EBITDA | $11,070 | $14,246 |
(a) Includes for three months ended April 3, 2021 and March 28, 2020, respectively, depreciation and amortization of $5,236 and $5,307, in cost of sales and $1,925 and 1,825, presented in the consolidated statements of operations and comprehensive income with the balance in research and development.
(b) Equity-based compensation (income) expense for the three months ended April 3, 2021 resulted from awards granted under the Company’s current equity based compensation plan (2021 Plan) and compensation costs as well as the change in fair market value of accrued equity-based compensation related to the BV LLC Phantom Profits Interest Plan (Phantom Plan) due to expected pricing with our IPO. Equity compensation expenses for the three months ended March 28, 2020 represents compensation from the Company’s management incentive plan and Phantom Plan as well as the change in fair market value of accrued equity-based compensation related to the plans due to the impact of the COVID-19 pandemic on our business.
(c) Primarily represents costs related to the CEO transition.
(d) Foreign currency impact represents realized and unrealized gains and losses from fluctuations in foreign currency and is included within other (income) loss in the consolidated statements of operations and comprehensive income.
(e) Primarily represents costs incurred as a result of the Bioness Acquisition.
(f) Represents CartiHeal equity investment losses.
(g) Other non-recurring costs primarily includes charges associated with potential strategic transactions, such as potential acquisitions and preparing to become a public company, primarily accounting and legal fees.
We present Adjusted EBITDA, a non-GAAP financial measure, because we believe it is a useful indicator of our operating performance. Our management uses Adjusted EBITDA principally as a measure of our operating performance and believes that Adjusted EBITDA is useful to our investors because it is frequently used by securities analysts, investors and other interested parties frequently use it in their evaluation of the operating performance of companies in industries similar to ours. Our management also uses Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. We define Adjusted EBITDA as net income (loss) before depreciation and amortization, provision of income taxes and interest expense, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include equity compensation, change in fair value of contingent consideration, Bioness acquisition costs, succession and transition charges, loss on impairment of intangible assets, losses associated with debt refinancing, foreign currency impact and other non-recurring costs. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation of corporate overhead costs is determined based on various methods but is primarily based on a ratio of net sales by segment to total consolidated net sales.
Net sales
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| U.S. | $74,538 | $71,970 | $2,568 | 3.6% |
| International | 7,240 | 6,675 | 565 | 8.5% |
| Net Sales | $81,778 | $78,645 | $3,133 | 4.0% |
21
U.S.
Net sales increased $2.6 million, or 3.6%. The changes in net sales by vertical are as follows:
| •Bone Graft Substitutes | $4.5 | million |
| •Pain Treatments and Joint Preservation | $(0.3) | million |
| •Restorative Therapies | $(1.6) | million |
Bone Graft Substitutes increased primarily due to sales volume growth. Pain Treatments and Joint Preservation decreased due to volume, offset by more treatments being sold under contracts with major insurers at lower prices. Restorative Therapies decreased due to lower sales volume.
International
Net sales increased $0.6 million, or 8.5%, primarily due to sales volume within our Pain Treatments and Joint Preservation vertical.
Gross profit and gross margin
(in thousands, except for percentage)
| Gross profit | Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | |
|---|---|---|---|---|
| U.S. | $54,615 | $52,686 | $1,929 | 3.7% |
| International | 4,941 | 4,550 | 391 | 8.6% |
| $59,556 | $57,236 | $2,320 |
| Gross margin | Three Months Ended April 3, 2021 | March 28, 2020 | Change |
|---|---|---|---|
| U.S. | 73.3% | 73.2% | 0.1% |
| International | 68.2% | 68.2% | —% |
| Total | 72.8% | 72.8% | —% |
U.S.
Gross profit increased $1.9 million, or 3.7%, primarily due to the increase in net sales. Gross margin remained consistent with the prior year comparable period.
International
Gross profit increased $0.4 million, or 8.6%, primarily due to the increase in net sales. Gross margin remained consistent with the prior year comparable period.
Selling, general and administrative expense
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Selling, general and administrative expense | $34,686 | $40,276 | $(5,590) | (13.9)% |
Selling, general and administrative expenses decreased $5.6 million, or 13.9%, primarily due to a higher change in fair value of our accrued equity-based compensation resulting in an increased net recovery of expense compared to the prior year of $16.0 million. The change in fair value during the three months ended April 3, 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price. The change in fair value during the three months ended March 28, 2020 was due to the impact of the COVID-19 pandemic on our business.
This decrease was partially offset by increases in the following areas:
| •Compensation related expenses | $5.5 | million |
| •Legal and accounting expenses primarily as a result of our acquisition of Bioness | $3.2 | million |
| •Equity compensation excluding change in the fair value | $1.1 | million |
22
Research and development expenses
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Research and development expense | $947 | $2,146 | $(1,199) | (55.9)% |
Research and development expense decreased by $1.2 million, or 55.9%, primarily due to a higher change in fair value of our accrued equity-based compensation resulting in an increased net recovery of expense totaling $1.3 million. The change in fair value during three months ended April 3, 2021 was due to adjustments to reflect the difference between the expected pricing from the pending IPO and the actual offering price. The change in fair value during the three months ended March 28, 2020 was due to the impact of the COVID-19 pandemic on our business.
Depreciation and amortization
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Depreciation and amortization | $1,925 | $1,825 | $100 | 5.5% |
Depreciation and amortization remained consistent with the three months ended March 28, 2020.
Other (income) expense
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Interest (income) expense | $(2,876) | $2,381 | $(5,257) | NM |
| Other expense | $419 | $83 | $336 | NM |
NM = Not meaningful
Interest (income) expense changed $5.3 million compared to the three months ended March 28, 2020. During the three months ended April 3, 2021, in conjunction with our IPO, we settled our equity participation right (EPR) liability resulting in interest income of $2.8 million. In addition, the change in the fair value of our interest rate swap resulted in interest income of $1.6 million during the three months ended April 3, 2021 compared to interest expense of $1.1 million during the three months ended March 28, 2020.
Other expense increased $0.3 million primarily due to $0.5 million in net losses related to our equity investment in CartiHeal.
Income tax expense
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Income tax (benefit) expense | $(73) | $39 | $(112) | NM |
| Effective tax rate | 0.3% | 0.4% | (0.1)% |
Income tax impact was nominal during the first quarter of 2020 and 2021. Our effective tax rate is expected to increase during 2021 primarily due to the change in structure resulting from our IPO and associated Up C partnership structure as well as the impact of non-deductible stock option expense during 2021.
Noncontrolling interest
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Continuing LLC Owner | $(81) | $— | $(81) | NM |
| Harbor | 489 | 458 | 31 | 6.7% |
| Total | $408 | $458 | $(51) |
Subsequent to the IPO and Transactions, we are the sole managing member of BV LLC and own 72.2%. We have a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, we consolidate the financial results of BV LLC and report a non-controlling interest representing the 27.8% which is owned by the Continuing LLC Owner. For the period subsequent to the IPO, there was a nominal impact as a result of this noncontrolling interest.
Our partial ownership and exclusive Collaboration Agreement continues to result in a variable interest in Harbor and consolidation into our financial statements. The noncontrolling interest was 91.2% as of April 3, 2021 and there was a nominal increase in the loss attributable to the Harbor noncontrolling interest as compared to the three months ended March 28, 2020.
Segment Adjusted EBITDA
Adjusted EBITDA for each of our reportable segments is as follows:
(in thousands, except for percentage)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| U.S. | $9,998 | $13,712 | $(3,714) | (27.1)% |
| International | $1,072 | $534 | $538 | 100.7% |
U.S.
Adjusted EBITDA decreased $3.7 million or 27.1% primarily due higher public company costs of $1.3 million and the previously discussed increase in compensation related charges. These decreases were partially offset by a $1.9 million increase in gross profit resulting from the increase in sales.
International
Adjusted EBITDA increased $0.5 million or 100.7% primarily due to a $0.4 million increase in gross profit resulting from the increase in sales.
Liquidity and Capital Resources
Our principal liquidity needs have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. We expect these needs to continue as we develop and commercialize new products and further our expansion into international markets. We believe that our existing cash and cash equivalents, borrowing capacity under our revolving credit facility, cash flow from operations, and net proceeds from our IPO will be enough to meet our anticipated cash requirements for at least the next twelve months. We may require additional liquidity as we continue to execute our business strategy. Negative impacts to our liquidity would include a decline in sales of our products, including declines due to changes in our customers’ ability to obtain third-party coverage and reimbursement for procedures that utilize our products, increased pricing pressures resulting from intensifying competition and cost increases, as well as general economic and industry factors. We anticipate that to the extent that we require additional liquidity, we will obtain funding through the incurrence of other indebtedness, additional equity financings or a combination of these potential sources of liquidity. In addition, we may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, or making capital expenditures. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our products, future revenue streams or product candidates, or to grant licenses on terms that may not be favorable to us. The covenants under our credit agreement limit our ability to obtain additional debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies.
Initial Public Offering
On February 16, 2021, in connection with our IPO, we issued and sold 9,200,000 shares of our Class A common stock at a price to the public of $13.00 per share, resulting in gross proceeds to us of approximately $119.6 million, before deducting the underwriting discount, commissions and estimated offering expenses payable by us.
We are a holding company and have no material assets other than our ownership of LLC Interests and no independent means of generating revenue. The limited liability company agreement of BV LLC provides for the payment of certain distributions to the Continuing LLC Owner and us in amounts sufficient to cover the income taxes imposed on such members with respect to the allocation of taxable income from BV LLC as well as to cover our obligations under the Tax Receivable Agreement (the TRA). Additionally, in the event we declare any cash dividend, we intend to cause BV LLC to make distributions to us, in an amount sufficient to cover such cash dividends declared by us. Deterioration in the financial condition, earnings, or cash flow of BV LLC and its subsidiaries for any reason could limit or impair their ability to pay such distributions. In addition, the terms of our financing arrangements, including the 2019 Credit Agreement, contain covenants that may restrict BV LLC and its subsidiaries from paying such distributions, subject to certain exceptions. Further, BV LLC is generally prohibited under Delaware law from making a distribution to a member to the extent that, at the time of the distribution, after giving effect to the distribution, liabilities of BV LLC (with certain exceptions), as applicable, exceed the fair value of its assets. Subsidiaries of BV LLC are generally subject to similar legal limitations on their ability to make distributions to BV LLC. If we do not have sufficient funds to pay taxes or other liabilities or to fund our operations, we may have to borrow funds, which could materially adversely affect our liquidity and financial condition and subject us to various restrictions imposed by any such lenders. To the extent that we are unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.
In addition, under the TRA, we are required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that we actually realize (or in certain circumstances are deemed to realize), as a result of (1) increases in the tax basis of assets of BV LLC resulting from (a) any future redemptions or exchanges of LLC Interests, and (b) certain distributions (or deemed distributions) by BV LLC and (2) certain other tax benefits arising from payments under the TRA. We expect the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income we generate in the future, and the federal tax rates then applicable. Any payments made by us to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us.
Cash and cash equivalents as of April 3, 2021 totaled $124.2 million compared to $86.8 million as of December 31, 2020. The increase in cash was primarily due to the following:
(in thousands)
| Three Months Ended April 3, 2021 | March 28, 2020 | Change $% | ||
|---|---|---|---|---|
| Net cash from operating activities | $(18,042) | $17,691 | $(35,733) | NM |
| Net cash from investing activities | (46,648) | (451) | (46,197) | NM |
| Net cash from financing activities | 107,526 | 48,782 | 58,744 | 120.4% |
| Effect of exchange rate changes on cash | (221) | (260) | 39 | (15.0)% |
| Net change in cash, cash equivalents and restricted cash | $42,615 | $65,762 | $(23,147) | (35.2)% |
NM = Not Meaningful
Operating Activities
Net cash from operating activities decreased $35.7 million primarily due to the following:
- Settlement of the remaining 183,078 units with the sole MIP awardee for $10.8 million and a final bonus of $1.5 million;
- Compensation and annual incentive plan payments increased $7.7 million;
- Payment of directors and officers annual insurance premiums for $4.6 million;
- Completed and potential acquisition expenses as well as other nonrecurring costs of $3.6 million;
- Settlement of our EPR liability for $3.3 million and;
- Higher inventory purchases of $2.7 million.
Investing Activities
Cash flows used in investing activities increased $46.2 million primarily due to the $45.8 million paid for the Bioness acquisition.
Financing Activities
Cash flows provided by financing activities increased $58.7 million primarily due to the $110.4 million in net proceeds from the issuance of Class A common stock sold during our IPO, partially offset with no draws on our revolving credit facility compared to prior year. There was also a $3.8 million increase in debt payments due to the timing of our quarter ends.
Credit Facilities
There have been no material changes to our outstanding indebtedness or the terms of and available borrowing capacity under our credit facilities as disclosed in our 2020 10-K. We were in compliance with all required financial covenants as of April 3, 2021.
Other
For information regarding Commitments and Contingencies, refer to Note 9. Commitments and contingencies to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.
Off-balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Contractual Obligations
We acquired leases as part of the Bioness Acquisition, which resulted in increases to contractual lease commitments previously disclosed in our 2020 10-K of $824, $808, $775, $776 and $638 for the years ended December 31, 2021, 2022, 2023, 2024 and 2025, respectively.
Critical Accounting Estimates
Our discussion of operating results is based upon the unaudited condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are detailed in Item 7 of our 2020 10-K, except for the following:
Contingent Consideration
The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue and the probability of achieving the specific targets. After the initial valuation, the Company will use its best estimate to measure contingent consideration at each subsequent reporting period. Gains and losses are recorded with selling, general and administrative expenses within the consolidated statements of operations and comprehensive income.
Recently Issued Accounting Pronouncements
Refer to Note 1. Organization, in the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued accounting pronouncements.
Controls and procedures
As filed, 1,394 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of April 3, 2021.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 610 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading Risk Factors included in our 2020 10-K, which could materially affect our businesses, financial condition, or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results. There have been no material changes in our risk factors from those described in our 2020 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-04-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-04-03 | $81.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-01-01 to 2021-04-03 | $22.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-01-01 to 2021-04-03 | $59.6m | us-gaap:GrossProfit |
| Research and development | 3 months2021-01-01 to 2021-04-03 | $947.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-01-01 to 2021-04-03 | $34.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-01-01 to 2021-04-03 | $22.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-01-01 to 2021-04-03 | −$73.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-04-03 | $24.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-04-03 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-04-03 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-04-03 | 41,797,882 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2021-01-01 to 2021-04-03 | −$18.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2021-01-01 to 2021-04-03 | $1.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-04-03 | $124.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-04-03 | $270.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-04-03 | $643.1m | us-gaap:Assets |
| Current liabilities | At period end2021-04-03 | $149.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-04-03 | $422.8m | us-gaap:Liabilities |
| Long-term debt | At period end2021-04-03 | $169.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-04-03 | $15.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-04-03 | $142.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-21-010090. Last ingested by Listed: Nov 14, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.